Literature DB >> 25390078

Preoperative predictors of pathological lymph node metastasis in patients with renal cell carcinoma undergoing retroperitoneal lymph node dissection.

Kara N Babaian1, Dae Y Kim2, Patrick A Kenney3, Christopher G Wood2, Joseph Wong2, Christopher Sanchez2, Justin E Fang2, Jonathan A Gerber2, Adin Didic2, Adelani Wahab2, Vishnukamal Golla2, Cristina Torres2, Pheroze Tamboli4, Wei Qiao5, Surena F Matin2, Christopher G Wood2, Jose A Karam6.   

Abstract

PURPOSE: Patients with locally advanced renal cell carcinoma represent a subset that may benefit from retroperitoneal lymph node dissection. We identified preoperative clinical predictors of positive lymph nodes in patients with renal cell carcinoma without distant metastasis who underwent retroperitoneal lymph node dissection.
MATERIALS AND METHODS: We retrospectively analyzed data on a consecutive cohort of 1,270 patients with cTany Nany M0 renal cell carcinoma who were treated at a single institution from 1993 to 2012. Multivariate analysis was performed to determine preoperative predictors of pathologically positive lymph nodes in patients who underwent retroperitoneal lymph node dissection. A nomogram was developed to predict the probability of lymph node metastasis. Overall, cancer specific and recurrence-free survival was estimated using the Kaplan-Meier Method.
RESULTS: We identified 1,270 patients with renal cell carcinoma without distant metastasis who had (564) or did not have (706) retroperitoneal lymph node dissection performed. Of the 564 patients 131 (23%) and 433 (77%) had pN1 and pN0 disease, and 60 (37%) and 29 (7.2%) had cN1pN0 and cN0pN1 disease, respectively. ECOG PS, cN stage, local symptoms and lactate dehydrogenase were associated with nodal metastasis on multivariable analysis. A nomogram was developed with a C-index of 0.89 that demonstrated excellent calibration. Differences in overall, cancer specific and recurrence-free survival among pNx, pN0 and pN1 cases were statistically significant (p <0.001).
CONCLUSIONS: Local symptoms, ECOG PS, cN stage and lactate dehydrogenase were independent predictors of lymph node metastasis in patients who underwent retroperitoneal lymph node dissection. Our predictive nomogram using these factors showed excellent discrimination and calibration.
Copyright © 2015 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  carcinoma; kidney; lymph node dissection; neoplasm metastasis; nephrectomy; renal cell

Mesh:

Year:  2014        PMID: 25390078     DOI: 10.1016/j.juro.2014.10.096

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  14 in total

1.  Valuation of lymph node dissection in localized high-risk renal cell cancer using X-tile software.

Authors:  Wei Zhuang; Jiabi Chen; Yining Li; Weihui Liu
Journal:  Int Urol Nephrol       Date:  2019-10-14       Impact factor: 2.370

2.  Canadian Urological Association guideline for followup of patients after treatment of non-metastatic renal cell carcinoma.

Authors:  Wassim Kassouf; Leonardo L Monteiro; Darrel E Drachenberg; Adrian S Fairey; Antonio Finelli; Anil Kapoor; Jean-Baptiste Lattouf; Michael J Leveridge; Nicholas E Power; Frederic Pouliot; Ricardo A Rendon; Robert Sabbagh; Alan I So; Simon Tanguay; Rodney H Breau
Journal:  Can Urol Assoc J       Date:  2018-05-31       Impact factor: 1.862

Review 3.  Sentinel lymph node biopsy in renal malignancy: The past, present and future.

Authors:  Tharani Mahesan; Alberto Coscione; Ben Ayres; Nick Watkin
Journal:  World J Nephrol       Date:  2016-03-06

Review 4.  [Why have tyrosine kinase inhibitors failed in the adjuvant situation and do checkpoint inhibitors make more sense?]

Authors:  Susanne Krege
Journal:  Urologe A       Date:  2020-02       Impact factor: 0.639

5.  Accuracy of clinical nodal staging and factors associated with receipt of lymph node dissection at the time of surgery for nonmetastatic renal cell carcinoma.

Authors:  Kushan D Radadia; Zorimar Rivera-Núñez; Sinae Kim; Nicholas J Farber; Joshua Sterling; Marissa Falkiewicz; Parth K Modi; Sharad Goyal; Rahul Parikh; Robert E Weiss; Isaac Y Kim; Sammy E Elsamra; Thomas L Jang; Eric A Singer
Journal:  Urol Oncol       Date:  2019-07-05       Impact factor: 3.498

Review 6.  Adjuvant Therapy for High Risk Localized Kidney Cancer: Emerging Evidence and Future Clinical Trials.

Authors:  Andrew T Lenis; Nicholas M Donin; David C Johnson; Izak Faiena; Amirali Salmasi; Alexandra Drakaki; Arie Belldegrun; Allan Pantuck; Karim Chamie
Journal:  J Urol       Date:  2017-05-04       Impact factor: 7.450

Review 7.  The rationale and the role of lymph node dissection in renal cell carcinoma.

Authors:  Umberto Capitanio; Bradley C Leibovich
Journal:  World J Urol       Date:  2016-06-30       Impact factor: 4.226

Review 8.  The contemporary role of lymph node dissection in the management of renal cell carcinoma.

Authors:  Piotr Zareba; Jehonathan H Pinthus; Paul Russo
Journal:  Ther Adv Urol       Date:  2018-08-20

9.  Predictive and prognostic effect of inflammatory lymphadenopathies in renal cell carcinoma.

Authors:  Fabio Muttin; Angela Pecoraro; Alessandro Larcher; Paolo Dell'Oglio; Alessandro Nini; Francesco Cianflone; Francesco Trevisani; Federico Dehò; Alberto Briganti; Andrea Salonia; Francesco Montorsi; Roberto Bertini; Umberto Capitanio
Journal:  World J Urol       Date:  2018-07-25       Impact factor: 4.226

10.  Dissecting the role of lymphadenectomy in the management of renal cell carcinoma: past, present, and future.

Authors:  Alain Kaldany; Zev R Leopold; Juliana E Kim; Hiren V Patel; Arnav Srivastava; Alexandra L Tabakin; Eric A Singer
Journal:  Kidney Cancer J       Date:  2020-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.